|Bevacizumab plus irinotecan in recurrent glioblastoma multiforme|
JJ Vredenburgh, A Desjardins, JE Herndon, J Marcello, DA Reardon, ...
Journal of clinical oncology 25 (30), 4722-4729, 2007
|Phase II trial of gefitinib in recurrent glioblastoma|
JN Rich, DA Reardon, T Peery, JM Dowell, JA Quinn, KL Penne, ...
Journal of Clinical Oncology 22 (1), 133-142, 2004
|Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma|
JH Sampson, AB Heimberger, GE Archer, KD Aldape, AH Friedman, ...
Journal of clinical oncology 28 (31), 4722, 2010
|Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma|
JH Sampson, JH Carter, AH Friedman, HF Seigler
Journal of neurosurgery 88 (1), 11-20, 1998
|Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma|
PE Fecci, DA Mitchell, JF Whitesides, W Xie, AH Friedman, GE Archer, ...
Cancer research 66 (6), 3294-3302, 2006
|Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial|
M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ...
The Lancet Oncology 18 (10), 1373-1385, 2017
|Proteomic and immunologic analyses of brain tumor exosomes|
MW Graner, O Alzate, AM Dechkovskaia, JD Keene, JH Sampson, ...
The FASEB Journal 23 (5), 1541-1557, 2009
|Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma|
S Kunwar, S Chang, M Westphal, M Vogelbaum, J Sampson, G Barnett, ...
Neuro-oncology 12 (8), 871-881, 2010
|Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma|
DA Mitchell, W Xie, R Schmittling, C Learn, A Friedman, RE McLendon, ...
Neuro-oncology 10 (1), 10-18, 2008
|Immunotherapy response assessment in neuro-oncology: a report of the RANO working group|
H Okada, M Weller, R Huang, G Finocchiaro, MR Gilbert, W Wick, ...
The Lancet Oncology 16 (15), e534-e542, 2015
|Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients|
DA Mitchell, KA Batich, MD Gunn, MN Huang, L Sanchez-Perez, SK Nair, ...
Nature 519 (7543), 366-369, 2015
|Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme|
DA Reardon, MJ Egorin, JA Quinn, JN Rich, I Gururangan, ...
Journal of Clinical Oncology 23 (36), 9359-9368, 2005
|Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion|
A Lal, CA Glazer, HM Martinson, HS Friedman, GE Archer, JH Sampson, ...
Cancer research 62 (12), 3335-3339, 2002
|Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group|
S Kunwar, MD Prados, SM Chang, MS Berger, FF Lang, JM Piepmeier, ...
Journal of Clinical Oncology 25 (7), 837-844, 2007
|Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly …|
DA Reardon, G Akabani, R Edward Coleman, AH Friedman, HS Friedman, ...
Journal of Clinical Oncology 20 (5), 1389-1397, 2002
|Phase II trial of temozolomide in patients with progressive low-grade glioma|
JA Quinn, DA Reardon, AH Friedman, JN Rich, JH Sampson, ...
Journal of clinical oncology 21 (4), 646-651, 2003
|Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma|
JH Sampson, KD Aldape, GE Archer, A Coan, A Desjardins, AH Friedman, ...
Neuro-oncology 13 (3), 324-333, 2011
|Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the …|
JH Sampson, G Akabani, GE Archer, DD Bigner, MS Berger, AH Friedman, ...
Journal of neuro-oncology 65 (1), 27-35, 2003
|An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme|
JH Sampson, GE Archer, DA Mitchell, AB Heimberger, JE Herndon, ...
Molecular cancer therapeutics 8 (10), 2773-2779, 2009
|Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma|
JA Quinn, SX Jiang, DA Reardon, A Desjardins, JJ Vredenburgh, JN Rich, ...
Journal of Clinical Oncology 27 (8), 1262, 2009